Please login to the form below

Not currently logged in
Email:
Password:

Richard Sorian joins Fleishman-Hillard

He will lead the Washington office’s growing healthcare division
FleishmanHillard RIchard Sorian

Fleishman-Hillard has added senior public affairs experience to its healthcare team with the appointment of Richard Sorian to lead the healthcare division of its office in Washington, DC.

The newly appointed senior vice president and partner joins from the District of Columbia's Health Benefit Exchange Authority, where he was director of communications, education and outreach.

Before joining the Authority, Sorian was assistant secretary for public affairs at the US Department of Health and Human Services (HHS), acting as chief adviser to the secretary on major communications strategies, responsible for steering the department's public affairs activities.

A 30-year healthcare communications veteran, Sorian also spent seven years as vice president for public policy and external relations at the National Committee for Quality Assurance, and served as senior advisor to HHS secretary Donna Shalala during the Clinton administration.

“Richard's vast experience will offer our clients a unique perspective on today's evolving communications challenges, and help our office reach new heights in this most competitive of sectors,” said Kris Balderston, general manager of Fleishman-Hillard's Washington office.

Sorian declared himself 'tremendously pleased' to be joining Fleishman-Hillard.

21st January 2014

From: Marketing

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Anatomy Health

We are a health information design consultancy focused on developing simple, accessible and inclusive patient communications. From evaluating existing patient...

Latest intelligence

Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...

Infographics